Business
Alaunos Therapeutics Announces $2.0 Million Registered Direct Offering
HOUSTON, June 23, 2025 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (Nasdaq: TCRT) (the “Company”) today announced that it has entered into a definitive agreement with certain investors (the “SPA”) for the purchase and sale of an aggregate of 610,399 shares of common stock (or pre-funded warrants in lieu thereof) at a purchase price of $3.36 per share (or pre-funded warrant in lieu thereof) in a registered direct offering (the “Offering”) on June 20, 2025 based on the 5-day average Nasdaq offi
About this update from Alaunos Therapeutics, Inc.
[{"type":"image","alt":"Alaunos Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Alaunos Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":71,"url":"https://media.zenfs.com/en/globenewswire.com/fc44db75cac831d4f86f998f912e409c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/yQCyUlgYK14CK__4MwE3Ew--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTk5O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/fc44db75cac831d4f86f998f912e409c","width":300,"height":71}},"lazy":false},{"type":"text","content":"HOUSTON, June 23, 2025 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (Nasdaq: TCRT) (the “Company”) today announced that it has entered into a definitive agreement with certain investors (the “SPA”) for the purchase and sale of an aggregate of 610,399 shares of common stock (or pre-funded warrants in lieu thereof) at a purchase price of $3.36 per share (or pre-funded warrant in lieu thereof) in a registered direct offering (the “Offering”) on June 20, 2025 based on the 5-day average Nasdaq official closing price.","length":519,"tagName":"p"},{"type":"text","content":"The aggregate gross proceeds to the Company of this offering are expected to be approximately $2.0 million, before deducting the offering expenses payable by the Company. The Company currently intends to use the net proceeds of approximately $1.9 million from the offering for its obesity program and general corporate purposes. The transaction is expected to close on or about June 24, 2025, subject to the satisfaction of customary closing conditions.","length":453,"tagName":"p"},{"type":"text","content":"The registered direct offering is being made pursuant to a shelf registration statement on Form S-3 (File No. 333-266841) previously filed by the Company and declared effective by the U.S. Securities and Exchange Commission (“SEC”) on September 7, 2022. A final prospectus supplement and accompanying prospectus describing the terms of the proposed offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov.","length":458,"tagName":"p"},{"type":"text","content":"This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of such securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior t...